Lancet (London, England)AdultFemaleHumansMaleMiddle Aged
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
Emma Guttman-Yassky, Kenji Kabashima, Margitta Worm, Paula C Luna, H Chih-Ho Hong, Raj Chovatiya, Jonathan A Bernstein, Johannes S Kern, Benjamin D Ehst, Nina Magnolo, Pedro Herranz-Pinto, Linda Stein Gold, Howard Sofen, Andrew E Pink, Ehsanollah Esfandiari
Published: 202610.1016/S0140-6736(25)01865-3
Abstract
BACKGROUND: Rocatinlimab is a T cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor expressed on the surface of activated T cells. Two global phase 3 studies were performed to assess the…
Preview only. Read the full abstract at the source